A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Journal Volume
28
Journal Issue
23
Pages
5058
Date Issued
2022-12-01
Author(s)
Chen, San-Chi
Chen, Mei-Lu
Hsu, Meng-Chi
Kung, Ting-Fang
Yen, Chueh-Chuan
Abstract
Satisfactory treatment options for advanced leiomyosarcoma and liposarcoma are limited. The LEADER study (NCT03526679) investigated the safety and efficacy of lenvatinib plus eribulin.
Subjects
B-CELLS; BEVACIZUMAB; CHEMOTHERAPY; COMPLEMENT; PAZOPANIB; SURVIVAL; TRIALS
SDGs
Publisher
AMER ASSOC CANCER RESEARCH
Type
journal article